Fig. 1.

Evobrutinib reduces clinical and histological EAE. Oral treatment of C57/Bl6 mice with vehicle or 1, 3 or 10 mg/kg evobrutinib started 7 days prior to immunization with 75 µg conformational MOG1-117 protein. a Exposure was measured in the serum 1 h after oral dosing by LC–MS. b Clinical severity was assessed on a standard 0–5 scale. Spinal cords were isolated 60 days after EAE induction and stained for c overall immune cell infiltration (HE), d overall demyelination (LFB/PAS) and the infiltration of e B cells (B220⁺), f T cells (CD3⁺) and g macrophages (Mac3). Mean ± SEM or median is shown, n = 9–13, *p < 0.05, **p < 0.01, ***p < 0.001